As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
Transcript
How does the American Heart Association’s partnership with the Ad Council raise public awareness about high blood pressure?
I’m really excited about the Ad Council campaign, because what we want to do is create a sense of urgency in patients to understand that hypertension, high blood pressure, is dangerous. And even though they feel perfectly fine, the disease just marches along. So, we want to create the sense of urgency by showing people real-life people who have had the consequences of blood pressure that is not at ideal levels.
How is the American Heart Association spreading the word about the new hypertension guidelines to physicians?
We’re working with the American Medical Association to get the word out to physicians with the guidelines. We have new apps that will go to physicians to let them figure out exactly how best to handle their patients with these new guidelines. So, we’re doing a 2-pronged approached: we’re doing to patients and we’re also doing to healthcare professionals. So, everyone can start to understand what the new guidelines are and why they are so important.
Will many more people need medication under the new hypertension guidelines?
What we’re doing with the new guidelines that we don’t expect too many more people to need medication, what we really want people to understand is the lifestyle—they need to know they have high blood pressure, and then make lifestyle changes. And, then, some people will need medications, but we’re not expecting that huge numbers will.
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More